PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002 PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant